Compare DAC & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAC | AUPH |
|---|---|---|
| Founded | 1972 | 1993 |
| Country | Greece | Canada |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2006 | 2014 |
| Metric | DAC | AUPH |
|---|---|---|
| Price | $127.50 | $17.88 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $112.50 | $17.25 |
| AVG Volume (30 Days) | 62.9K | ★ 1.3M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.00% | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | N/A | $17.54 |
| Revenue Next Year | N/A | $15.74 |
| P/E Ratio | ★ $4.01 | $70.04 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $83.56 | $7.29 |
| 52 Week High | $135.21 | $18.40 |
| Indicator | DAC | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 46.76 | 73.42 |
| Support Level | $122.57 | $14.60 |
| Resistance Level | $134.25 | N/A |
| Average True Range (ATR) | 3.16 | 0.61 |
| MACD | -0.61 | 0.21 |
| Stochastic Oscillator | 31.40 | 84.13 |
Danaos Corp is an international owner of containerships. It provides international seaborne transportation services by operating vessels in the containership sector of the shipping industry. The company's customers include HMM, MSC, Yang Ming, Hapag Lloyd, ZIM, Maersk, COSCO, OOCL, ONE, PIL, Sealead, Niledutch, Samudera, OSC, and Arkas. Geographically, the company operates in Australia, Asia, Europe, and America, with maximum revenue from the Australia-Asia region. It has two reporting segments: Container vessels and Drybulk vessels segment. It generates the majority of its revenue from Container vessels.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.